Description
Mod GRF 1-29 & GHRP-2 Peptide Blend
GHRP-2 and Modified GRF 1-29 are synthetic peptides developed to support the regulation and stimulation of growth hormone release. When used together, they are often described as having complementary or synergistic effects on growth hormone secretion.
GHRP-2 is a synthetic growth hormone secretagogue that is believed to act through ghrelin receptors. Ghrelin is a naturally occurring 28–amino acid hormone involved in regulating appetite and stimulating growth hormone release, which is why it is often referred to as the “hunger hormone.” By binding to growth hormone secretagogue receptors (GHS-R1a), particularly in the pituitary, GHRP-2 is thought to promote the release of growth hormone.
Modified GRF 1-29 is an engineered analog of growth hormone-releasing hormone (GHRH). It contains the first 29 amino acids of the natural hormone, which are sufficient for receptor activation in the anterior pituitary’s somatotroph cells. Several amino acid substitutions have been introduced to improve resistance to enzymatic breakdown and extend its stability and activity in circulation.(3)
Both peptides have been investigated for their ability to stimulate growth hormone secretion when acting on the pituitary gland, either individually or in combination.(4)
Chemical Composition
- Modified GRF 1-29: C152H252N44O42; 3367.9 g/mol
- GHRP-2: C45H55N9O6; 817.9 g/mol
Alternative names:
- Modified GRF 1-29: also known as CJC-1295 without DAC
- GHRP-2: also known as pralmorelin or growth hormone-releasing peptide-2
Research Overview
General pharmacology and safety observations
Animal studies of growth hormone secretagogues such as GHRP-2 have shown limited systemic toxicity at doses that still produce growth hormone release. Observed effects have largely been restricted to mild changes in intestinal smooth muscle activity, with no major impacts reported on renal, respiratory, or cardiovascular systems in experimental settings.(5) These findings have led researchers to consider potential diagnostic or therapeutic applications in growth hormone deficiency and growth disorders.
Appetite stimulation and food intake
Because GHRP-2 interacts with ghrelin receptors beyond the pituitary, it has been associated with increased appetite. In a small human study, participants given GHRP-2 consumed significantly more food than those given placebo during controlled buffet testing, alongside elevated growth hormone levels.(6) This suggests a role in stimulating both hormonal release and feeding behavior.
Broader effects of growth hormone secretagogues
Reviews of this class of compounds suggest they may influence body composition and physiology in multiple ways, including increased lean mass, reduced fat mass, improved exercise capacity, and changes in metabolic rate. Some findings also indicate effects on sleep, bone turnover, and appetite regulation depending on the subject group studied.(7)
Growth hormone deficiency research
In studies involving individuals with growth hormone deficiency, GHRP-2 has been shown to stimulate growth hormone release via actions on both the pituitary gland and hypothalamic pathways. Additional effects on appetite and sleep regulation have also been observed, although the mechanisms are not fully understood.(8)
Longer-term studies in growth-impaired children showed sustained increases in growth hormone levels with repeated GHRP-2 administration, along with acceptable tolerability profiles.(9)
Hormonal response patterns
Clinical research in adult male subjects has shown that GHRP-2 administration can elevate not only growth hormone but also other endocrine markers such as ACTH, cortisol, and in some cases prolactin. These responses were observed in both younger and older adults, though the magnitude of growth hormone release tended to be greater in younger participants.(10)
Mechanistic pathways
GHRP-2 is believed to activate GHS-R1a receptors, triggering intracellular signaling cascades that ultimately promote growth hormone release. Meanwhile, Mod GRF 1-29 is thought to act on GHRH receptors in the anterior pituitary, initiating a cAMP-mediated signaling pathway that increases intracellular calcium and promotes hormone secretion.
When used together, these two mechanisms are proposed to complement each other, potentially enhancing pulsatile growth hormone release more than either compound alone.
IGF-1 and synergistic effects
Research suggests that both GHRP-2 and GHRH analogs like Mod GRF 1-29 can increase growth hormone levels, which in turn may raise insulin-like growth factor 1 (IGF-1). Some analyses report substantial increases in growth hormone release when these compounds are combined, with evidence pointing toward synergistic amplification of hormonal output compared to single-agent use.(11)
Reviews
There are no reviews yet.